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syndrome patients with dry eye syndrome
by two-dimensional-nano-liquid
chromatography coupled with tandem
mass spectrometry
Bing Li1*, Minjie Sheng1*, Jianhua Li2, Guoquan Yan3, Anjuan Lin1, Min Li1, Weifang Wang1 & Yihui Chen1
1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Shanghai, P.R. China, 2Ludwig-Maximilians-Universität
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We examined the tear film proteome of patients with Sjögren’s syndrome (SS) and dry eye syndrome (group
A), patients with dry eye symptoms (group B) and normal volunteers (group C). Tear samples were pooled
from 8 subjects from each group and were subjected to two-dimensional-nano-liquid chromatography
coupled with tandem mass spectrometry (2D-nano-LC-MS/MS). The tear breakup time for group A was
significantly reduced compared with group B and C (P , 0.001). Group A (Schirmer I test, 2.13 6 2.38 mm/
5 min) had markedly lower tear volume than group B (5.94 6 4.75 mm/5 min) and C (14.44 6 6.57 mm/
5 min) (P , 0.001). Group A had significantly higher normalized tear protein content (1.8291 6 0.2241 mg/mm)
than group B (1.0839 6 0.1120 mg/mm) (P 5 0.001) and C (0.2028 6 0.0177 mg/mm) (P 5 0.001). The
2D-nano-LC-MS/MS analysis identified a total of 435 proteins, including 182 (54.8%), 247 (74.4%) and 278
(83.7%) in group A, B, and C, respectively, with 56 (16.7%) proteins including defensin a1, clusterin and
lactotransferrin unique to group A. In conclusion, dry eye syndrome in SS patients is associated with an
altered proteomic profile with dysregulated expression of proteins involved in a variety of important cellular
process including inflammation, immunity, and oxidative stress.
D
ry eye syndrome is a multifactorial condition characterized by eye irritation symptoms, blurred and
fluctuating vision, tear film instability, increased tear osmolarity and ocular surface epithelial dysfunc-
tion1–4. Sjögren’s syndrome (SS) is an autoimmune disorder in which the exocrine glands are the principal
target organs, particularly the lachrymal and salivary glands5,6, and dry eyes are frequently are the presenting
symptoms of SS.
Multiple proteomics-based studies have identified several proteins and peptides as candidate SS biomarkers. A
proteomic analysis of the saliva of SS patients exhibited differences in the levels of a number of proteins such as a-
amylase precursor, carbonic anhydrase VI, and b-2 microglobulin compared to healthy controls7. Other studies
also reveal that lactoferrin is a tear-specific biomarker for SS while anti-transglutaminase, anti-histone, anti-SSA
and anti-SSB antibodies are saliva biomarkers of SS8,9. The ability to probe the protein content of human tear fluid
has enormous potential for deepening our understanding of the pathology of ocular and systemic diseases such as
SS and diabetes and enabling novel noninvasive tear-based diagnostic technologies.
Recently, electrospray ionization (ESI) tandem mass spectroscopy (MS/MS) has been used to identify novel
protein species in tears10–13. The number of proteins found in the tear film continues to grow; however, there is
disagreement in the literature regarding the number of proteins in the tear film and the functions of individual
proteins. Fung et al.14 reported that approximately 500 proteins were detected and unambiguously identified by
liquid chromatography (LC)/MS/MS. Some of these functions are thought to be protective by aiding the ocular
surface defense system, or maintain stability of the ocular surface by promoting interaction with other ligands
(i.e., lipid binding proteins). The up- or downregulation of these proteins may be indicative of disease mechan-
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The aims of this study were to examine and compare the tear film
proteome of SS, dry eye patients and normal volunteers using 2D-
LC-nano-MS/MS-based proteomics.
Methods
The study population. Eight subjects with SS and dry eye syndrome (group A) were
recruited for the study. SS was diagnosed according to the Fox criteria16. Dry eye
syndrome was diagnosed by a modified Dry Eye Workshop classification17 and was
considered present if Schirmer I test , 5 mm and tear breakup time (BUT) , 5
seconds, and absent if Schirmer I test . 10 mm and BUT . 10 seconds. Eight patients
with dry eye symptoms (group B, Schirmer I test . 10 mm and BUT . 10 sec) but no
systemic diseases were also recruited. A subject was excluded if he or she 1) had a
history of ocular trauma or abnormality of the nasolacrimal drainage apparatus;
2) used eye drops within one month prior to the study, 3) had systemic immunologic
syndromes other than SS; or 4) any other ocular syndromes than dry eye syndrome.
Four acinae of the labial gland were taken from the patients and immediately
preserved in formalin for pathological examination. In addition, 8 age and sex-
matched healthy subjects who received regular physical checkup (group C) in the
same interim were included as normal controls.
The study protocol was approved by the Institutional Review Board of Shanghai
Tenth People’s Hospital and all study participants provided written informed
consent. The study was carried out in accordance with the Declaration of Helsinki.
Western blot assays. Five mL of blood was collected via the antecubital vein of
participants in group A, B, and C for measurement of anti-SSA/SSB antibodies using
commercially available kits as instructed by the manufacturer (Emoimraw,
Germany). The immunoblotting procedure was carried out as previously described18.
Sample collection and preparation. Tears were collected by placing a Schirmer strip
in the inferior fornix approximately 6 mm from the lateral canthus. The conjunctiva
was not anesthetized. The subjects were instructed to keep the eyes closed during the
5-min test. After the wet length was recorded, the strip was placed in a 1-mL amber
Eppendorf tube. Gloves were worn by the examiner and by all investigators handling
any tear film samples. All the samples were processed in a masked fashion. The
samples were placed immediately in ice transport tanks and stored at 280uC until
processed.
Proteins were extracted from the Schirmer strip by incubation in 1 mL Tris buffer
(pH 5 8.3) at 4uC for 10 h. After centrifugation at 12,000 g for 10 min, the super-
natants from all patients within each group were pooled and precipitated by acetone
as described previously19. Precipitated proteins were resuspended in 100 mL Tris
buffer and quantitated using the BCA assay kit (Pierce, Rockford, IL). The normalized
protein content in the tear samples pooled from all subjects from each group was
calculated using the following formula:
Normalized protein content~total protein=f ilterpaper wet length in Schirmer I test:
Then, 12.5 mg protein from each group was incubated with 25 mM ammonium
bicarbonate and 10 mM dithiothreitol (DTT) for 60 min at 56uC followed by
incubation with 25 mM iodoacetamide (IAA) for 30 min in the dark at room tem-
perature. Trypsin digestion was done at 37uC for 12 h. The resultant peptides were
dried and saved at 280uC.
Two-dimensional strong cation-exchange/reversed-phase nano-scale liquid
chromatography mass spectrometry. Extracted peptides were desalted using a
1.3 mL C18 solid phase extraction column (Sep-PakH Cartridge, Waters, Milford,
MA), dried using a vacuum centrifuge and resuspended with loading buffer (5 mM
ammonium formate containing 5% acetonitrile, pH 3.0), which were then separated
and analyzed by 2D-LC-nano-MS/MS. The experiments were performed on a Nano
Aquity UPLC system (Waters) connected to an LTQ Orbitrap XL mass spectrometer
(Thermo Electron, Bremen, Germany) equipped with an online nano-electrospray
ion source (Michrom Bioresources, Auburn, CA). A 180 mm 3 2.4 cm SCX column
(Waters), which was packed with a 5-mm PolySULFOETHYL Aspartamide (PolyLC,
Columbia, MD), was used for the first dimension for recovery of hydrophobic
peptides after a conventional salt step gradient. Then, a RP step gradient from 15% to
50% acetonitrile was applied to the SCX column as previously described18. The RP
analytical column (20 cm 3 75 mm), which was packed with a 1.7-mm Bridged Ethyl
Hybrid (BEH) C18 material (Waters), was used for the second dimension separation
to elute peptides using a three-step linear gradient, starting from 5% B to 45% B in
40 min (A: water with 0.1% formic acid; B: acetonitrile with 0.1% formic acid),
increased to 80% B in 3 min, and then to 5% B in 2 min. The electrospray voltage of
1.1 kV versus the inlet of the mass spectrometer was used.
LTQ Orbitrap XL mass spectrometer was operated in the data-dependent mode to
switch automatically between MS and MS/MS acquisition. Survey full-scan MS
spectra with two microscans (m/z 300–1800) were acquired in the Obitrap with a
mass resolution of 60,000 at 400 m/z, followed by ten sequential LTQ-MS/MS scans.
Dynamic exclusion was used with two repeat counts, 10 s repeat duration, and 60 s
exclusion duration. For MS/MS, precursor ions were activated using 35% normalized
collision energy at the default activation q of 0.25.
Data analyses. All MS/MS spectra were identified by using SEQUEST [v.28 (revision
12), Thermo Electron] against the human International Protein Index (IPI) database
(IPI human v3.45 Fasta with 71983 entries). To reduce false positive identification
results, a decoy database containing the reverse sequences was appended to the
database. The searching parameters were set up as follows: partial trypsin (KR)
cleavage with two missed cleavages was included for analysis, the variable
modification was oxidation of methionine, peptide mass tolerance was 20 ppm, and
fragment ion tolerance was 1 Da. The Trans Proteomic Pipeline software (revision
4.0) (Institute of Systems Biology, Seattle, WA) was then utilized to identify proteins
based upon corresponding peptide sequences with $95% confidence. The peptide
results were filtered by the Peptide Prophet18 with a P value over 0.95 and a Protein
Prophet19 probability of 0.95 was used for protein identification results. Spectral
counts (SC) correlate with protein abundance20. The relative abundance of individual
proteins was assessed by spectral counting, in which we counted the number of times
the unlabeled version of a protein was identified by the fragmentation spectra of its
peptides. Additionally, we normalized SC using the following formula:
Normalized SC~SC of specif ic protein|100=totalSC of each group
For analysis of the difference of abundance among the proteomes, proteins were
divided into three groups according to SC: the high abundance group (SC $ 50), the
medium abundance group (20 , SC , 49), and the low abundance group (SC , 20).
Significant upregulation was defined as a SC ratio $ 3 and SC distance $ 5; significant
downregulation was defined as a SC ratio # 0.33 and SC distance # 25. SC ratio was
calculated using the equation:
SC ratio~ tear protein SC of SS patientsð Þ=control SC
and SC distance was calculated using the following formula:
SC distance~ tear protein SC of SS patientsð Þ{ control SCð Þ:
Statistical analysis. Data were expressed as mean 6 standard deviation and
analyzed using the SPSS version 16.0 (SPSS, Chicago, IL). Chi-square tests and
Student’s t tests were performed and a P value of 0.05 or less was considered
significant in our study.




eye symptoms n 5 8
Patients with SS and dry
eye syndrome n 5 8
Age, years
Mean 61.75 56.38 60.13
Standard deviation 6.61 4.63 5.89
Gender
Male 4 4 4
Tear breakup time, sec 12.38 6 3.88 3.06 6 1.76 1.07 6 1.22
Schirmer I test, mm/5 min 14.44 6 6.57 5.94 6 4.75 2.13 6 1.88
Fluorescent test 0.00 6 0.00 8.44 6 6.18 26.49 6 0.99
Best corrected visual acuity 0.91 6 0.23 0.91 6 0.21 0.45 6 0.35
SSA/SSB antibody (1) 0 0 6
Lip gland biopsy (1) 0 0 8
SS: Sjögren’s syndrome.
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Results
Demographic and baseline characteristics of the study subjects.
Demographic and baseline characteristics of the study subjects are
summarized in Table 1. The subjects of the three groups were
matched in age and sex. Group A patients had a median duration
of symptoms for 10.5 (range, 8 to 14) years. The BUT for group A
patients was 1.07 6 1.022seconds, which was markedly reduced
compared with that of group B (P , 0.001) and that of group C
(P , 0.001). The BUT for group B patients was also markedly
reduced compared to that of group C (P , 0.001). In addition,
group A patients had a marked reduction in tear volumes (2.13 6
2.38 mm/5 min) compared to group B and C (P , 0.001 in both).
Furthermore, SSA/SSB antibodies were present in 75% (6/8) of the
sera samples of group A patients with dry eye syndrome, which was
not detected in group B and C.
Patients with SS and dry eye syndrome have increased normalized
protein content in tears. The total protein contents in tear samples
per Schirmer strip were 395.50 6 78.45, 499.41 6 145.59 and 423.58
6 151.77 mg in group A, B and C, respectively, with no apparent
difference statistically among the three groups (P 5 0.274). We
further determined the normalized protein content in tear samples.
The normalized tear protein content in group A was 1.8291 6
0.2241 mg/mm, which was markedly higher than that of group B
(1.0839 6 0.1120 mg/mm) (P 5 0.001) and group C (0.2028 6
0.0177 mg/mm) (P 5 0.001) (Fig. 1a).
Tear proteomic characteristics of the study subjects. The 2D-nano-
LC-MS/MS analysis identified a total of 435 unique proteins from the
tear samples, including 278 (83.7%) proteins in group A, 247 (74.4%)
proteins in group B and 182 (54.8%) proteins in group C. One
hundred forty-four (43.4%) proteins were shared among group A,
B and C. In addition, 62 (18.7%) proteins were present in group A
and B, 9 (2.7%) proteins were found in both group B and C, and 16
(4.8%) proteins were shared by group A and C. Fifty-six (16.7%)
proteins were unique to group A, 32 (9.6%) proteins to group B
and thirteen (3.9%) to group C (Fig. 1b). In addition, the percent-
age of high and low abundance proteins was comparable among the
three groups (P . 0.05) (Fig. 1c). Meanwhile, the percentage of
medium abundance proteins in group A was markedly higher than
that of group C (P , 0.05) (Fig. 1c) while the percentage of high
abundance proteins was markedly reduced in group A.
Changes in tear proteins of SS patients with dry eye syndrome. The
12 most upregulated proteins in tear fluids of group A are shown
in Table 2 and the 10 most downregulated proteins in tear
proteins of group A are shown in Table 3. Tear proteins unique
to group A included proteins in host defense such as defensin a1
and lactotransferrin, proteins involved in the immune response or
Figure 1 | (a) Normalized protein content in tear samples from healthy subjects (A), patients with dry eye symptoms (B) and Sjögren’s syndrome (SS)
patients with dry eye syndrome (C). Data are expressed as mean 6 sd of at least three independent experiments. P** 5 0.035, healthy subjects vs. SS
patients with dry eye syndrome and P*5 0.213 patients with dry eye symptoms vs. SS patients with dry eye syndrome. (b) Protein distribution in healthy
subjects (A), patients with dry eye symptoms (B) and SS patients with dry eye syndrome (C) identified by 2D-nano-LC-MS/MS. (c) Abundance of tear
proteins in healthy subjects (A), patients with dry eye symptoms (B) and SS patients with dry eye syndrome (C) The relative abundance of individual
proteins was assessed by spectral counting.
Table 2 | The 12 most upregulated tear proteins in Sjögren’s syndrome patients with dry eye syndrome
Accession No. Protein Name Spectral counts
A8K008 CDNA FLJ78387 115
NP_001002858 Annexin A2 isoform 1 94
P02787 Serotransferrin precursor 92
OTTHUMP00000167597 Keratin 4 90
P06702 Protein S100-A9 77
P98088 Mucin-5AC precursor (fragment) 59
P04083 Annexin A1 58
P13645 Keratin, type I cytoskeletal 10 50
P04264 Keratin, type II cytoskeletal 1 47
P05109 Protein S100-A8 41
P01024 Complement C3 precursor (fragment) 41
P60709 Actin, cytoplasmic 1 41
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inflammatory reaction such as neutrophil elastase 2 and C3,
and apoptosis-related proteins like clusterin and annexin
(Table 4).
Discussion
Tear proteomic profile of SS patients with dry eye syndrome may
offer important insight into the mechanisms of disease process at the
target organs and may lead to identification of biomarkers for the
conditions. In the current study, we examined the proteomic prop-
erties of tear fluids of SS patients with dry eye syndrome, patients with
dry eye symptoms and healthy subjects using nano-flow 2D-LC-ESI-
MS/MS. We identified a total of 435 proteins in the tear fluids from all
three groups together, suggesting the presence of a wealth of proteins
in the tear fluid. The findings indicate that the nano-flow 2D-LC-ESI-
MS/MS approach may yield a promising proteomic profile of tear
proteins in SS patients with dry eye syndrome from relatively small
amounts of samples. We also identified 56 proteins that were
uniquely present in the tear fluid of SS patients with dry eye syn-
drome, which include proteins in the host defense, immune response,
inflammation and apoptosis. The findings suggest that the develop-
ment of dry eye syndrome in SS is a complicated process involv-
ing proteins of multiple body systems with participation of novel
proteins. These proteins are involved in the inflammatory response
Table 3 | The 10 most downregulated tear proteins in Sjögren’s
syndrome patients with dry eye syndrome
Accession Protein Name SC
Q5DSM0 Growth-inhibiting protein 12 516
P31025 Lipocalin-1 precursor 507
P12273 Prolactin-inducible protein precursor 191
Q8N5K4 Igha1 Protein 152
P01833 Polymeric immunoglobulin receptor precursor 85
Q9GZZ8 Extracellular glycoprotein lacritin precursor 80
P61626 Lysozyme C precursor 60
Q16378 Proline-rich protein 4 precursor 56
P01036 Cystatin-S precursor 29
P13647 Keratin, type II cytoskeletal 5 28
Table 4 | Changes and functional classification of tear proteins in Sjögren’s syndrome patients with dry eye syndrome
Accession Protein Name
Host defense proteins
P59665 Defensin, a1 upregulated
P81605 Dermcidin upregulated
P80511 S100 calcium binding protein A12 upregulated
P31151 S100 calcium binding protein A7 upregulated
Q71DI3 Histone 1, H2Bd upregulated
P20160 Azurocidin 1 (cationic antimicrobial protein 37) upregulated
Q5DSM0 Lactotransferrin downregulated
P61626 Lysozyme (renal amyloidosis) downregulated
Proteins involved in the immune response and inflammatory reaction
P02765 a-2-Hs-glycoprotein upregulated
P05155 Serpin peptidase inhibitor, clade G (C1 inhibitor) upregulated
P08246 Elastase 2, neutrophil upregulated
P04264 Keratin 1 (epidermolytic hyperkeratosis) upregulated
P00734 Coagulation factor II (thrombin) upregulated
P02787 Transferrin upregulated
P02763 Orosomucoid 1 upregulated
P01024 Complement component 3 upregulated
P19652 Orosomucoid 2 upregulated
P0C0L4 Complement component 4A upregulated
P02652 Apolipoprotein A- II __
Apoptosis-related proteins
P55072 Valosin-containing protein upregulated
O43707 Actinin, a4 upregulated
P00441 Superoxide dismutase 1, soluble upregulated
P27797 Calreticulin upregulated
P10909 Clusterin upregulated
P08107 Heat shock 70 Kda protein 1A upregulated
Q96BY2 Modulator Of apoptosis 1 upregulated
P04792 Heat shock 27 Kda protein 1 upregulated
P14174 Macrophage migration inhibitory factor upregulated
P04083 Annexin A1 upregulated
P30101 Protein disulfide isomerase family A, member 3 upregulated
P00734 Coagulation factor II (thrombin) upregulated
P23528 Cofilin 1 (non-muscle) upregulated
P47895 Aldehyde dehydrogenase 1 family, member A3 upregulated
Q15121 Phosphoprotein enriched in astrocytes 15 upregulated
P63104 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein upregulated
P12814 Actinin, a1 upregulated
P08758 Annexin A5 downregulated
P31944 Caspase 14, apoptosis-related cysteine peptidase downregulated
P32119 Peroxiredoxin 2 downregulated
P07858 Cathepsin B downregulated
P04179 Superoxide dismutase 2, mitochondrial __
P09211 Glutathione S-transferase PI __
Q04760 Glyoxalase I __
Q6NUS1 Programmed cell death 6 interacting protein __
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(a-2-HS-glycoprotein, coagulation factor II, transferrin, and oroso-
mucoid 1 and 2), biosynthesis of IL-8 (apolipoprotein A-II and elas-
tase 2) and activation of the host immune response and the
inflammatory response (serpin peptidase inhibitor, clusterin, keratin
1, C3 and 4A). Gene co-expression modules related to primary SS and
primary SS/MALT lymphoma were significantly enriched with genes
known to be involved in the immune/defense response, apoptosis, cell
signaling, gene regulation, and oxidative stress21. We further found in
this study that tear proteins in SS patients with dry eye syndrome and
patients with dry eye symptoms exhibited a marked increase in the
contents of proteins involved in the immune response and stress
response, development and differentiation. These proteins also inter-
act with one another and they also show increased oxidative activities.
The findings indicate that proteins in the tear fluid of SS patients with
dry eye syndrome and patients with dry eye symptoms are more
likely the result of the host stress response, which is consistent with
the findings by Hu et al21.
Beta-2-microglobulin, lactoferrin, immunoglobulin (Ig) kappa
light chain, polymeric Ig receptor, lysozyme C and cystatin C
were found to be involved in all stages of SS22. Two presumed
proline-rich proteins, amylase and carbonic anhydrase VI, were
downregulated in SS patients. In our study, we found that poly-
meric immunoglobulin receptor precursor, cystatin-S precursor
and proline-rich protein 4 precursor were downregulated in the
tear fluids of group A patients. Lactotransferrin, which was
downregulated in the tear fluids of group A patients in the cur-
rent study, is a secreted protein and possesses antimicrobial
activities against bacteria, fungi and viruses23. The protein acts
downstream of the inflammatory and immune response cascade
and could modulate the host response to bacteria and the
immune response. Defensin belongs to the a-defensin family
and is a secreted protein. Defensin 1a, which was upregulated
in the tear fluid of SS patients with dry eye syndrome in this
study, is capable of inhibiting the replication of viruses and
synthesis of viral proteins24. Lysozyme, which has bacteriolytic
activities, was downregulated in the tear fluid of SS patients with
dry eye syndrome. Our findings that lactotransferrin and lyso-
zymes were downregulated in the tear fluid of group A patients
indicate that the ocular surface defense system becomes lessened
in group A patients, which may render the patients more sus-
ceptible to microbial infections.
Consistent with the findings by Giusfi et al25, proteins related to
acute and chronic inflammation or involved in oxidative stress
injury in this study were upregulated. We found that S100 A 12
and S100 A7 were upregulated in the tear fluids of group A
patients. S100 proteins are calcium binding proteins. The secre-
tion of S100 A12 is induced by TNF and S100 A12 is highly
expressed in the inflammatory response26. Other members of the
S100 family including S100 A6, S100 A8, S100 A9, and S100 A11
were also upregulated in the tear fluids of group A patients (data
not shown), indicating their involvement in the inflammatory
response. In addition, proteins associated with apoptosis were
markedly upregulated or downregulated. Superoxide dismutase 1
and heat shock proteins were markedly upregulated while perox-
iredoxin 2 was downregulated.
Our results lend support to the concept that autoimmunity-
mediated dry eye disease has an inflammatory component27.
Overexpressed proteins were interferon-inducible or were related
to lymphocyte filtration and antigen presentation known to be
involved in the pathogenesis of primary SS28. In the current study,
neutrophil elastase 2, a-2-HS–glycoprotein, C3, Orosomucoid 1
and 2 were significantly upregulated while APO A-II and clusterin
showed no apparent changes from normal controls, suggesting the
presence of enhanced immune and inflammatory response at
the ocular surface. Complement C3 is a pivotal component of
the complement system, interacts with C3d and CR2, and plays
a critical role in the activation and proliferation of B cells. In C3
knockout SS mice, SS was diminished or abolished29. In addi-
tion, apoptosis of ductal cells in the exocrine glands was
decreased and caspase-3 levels declined with apparent reduction
in the infiltration of leukocytes into the submandibular gland
and diminished production of autoantibodies. Cuida et al.30
reported that complement regulatory proteins in the saliva of
SS patients including CD59, CD55, CD46 and clusterin could
inhibit the activation of complements in tissues. We found that
these proteins were reduced in levels or absent in the tear fluids
of group A patients, indicating that complements may show
unrestrained activities in the tissues. We found here that C3
was upregulated in the tear fluid of group A patients. Given
its pivotal role in immune response and inflammation, C3
may be an important molecule for targeting and as a predictor
of patient outcomes.
In conclusion, we have demonstrated that dry eye syndrome in SS
patients is associated with an altered proteomic profile with dysre-
gulated expression of proteins involved in a variety of important
cellular process including inflammation, immunity, and oxidative
stress. These findings suggest broad derangement in tear proteins
in SS patients with dry eye syndrome. Furthermore, SS and dry eye
have similar pathologies such as increased apoptosis, inflammation
at the ocular surface, immune response and cytoskeletal remodeling.
Further characterization of these proteins could provide potential
diagnostic markers and therapeutic targets that may lead to better
outcomes for these patients.
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syndrome. Arthritis Rheum 56, 3588–3600 (2007).
29. Nguyen, C. Q., Kim, H., Cornelius, J. G. & Peck, A. B. Development of Sjögren’s
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